Pyramid Biosciences Names Nushmia Khokhar, MD, as Chief Medical Officer
August 8, 2022- Dr. Khokhar will oversee the advancement and expansion of the Company’s clinical pipeline
- Dr. Khokhar joins Pyramid Biosciences from Umoja Biopharma where she served as Chief Medical Officer
WALTHAM, Mass.–(BUSINESS WIRE)–#PyramidBiosciences–Pyramid Biosciences, Inc., a Boston-based, clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer and other serious diseases, today announced the expansion of its senior leadership team. Nushmia Khokhar, MD has joined the company as Chief Medical Officer, where she will oversee the advancement and expansion of the Company’s clinical pipeline.
“Dr. Khokhar has a proven track record of successfully bringing novel oncology compounds through clinical development to global approval,” said CEO of Pyramid Biosciences, Brian Lestini, MD, PhD. “We are looking forward to Dr. Khokhar’s leadership of our clinical programs during this important growth stage of our company.”
Prior to joining Pyramid Biosciences, Dr. Khokhar served as Chief Medical Officer at Umoja Biopharma, a multi-platform, immuno-oncology company based in Seattle, WA. In this capacity, Dr. Khokhar oversaw Umoja’s clinical development, operations, and regulatory functions. Prior to joining Umoja, Dr. Khokhar was the Senior Vice President & Head of Clinical Development at Autolus Therapeutics, where she played a critical role in advancing the company’s autologous CAR T-cell products and clinical programs. Prior to that, Dr. Khokhar held numerous roles at Janssen Oncology, a subsidiary of Johnson & Johnson (NYSE: JNJ) where she led several successful clinical trials, directed the Phase 3 registration trial of trabectedin (YONDELIS®) in soft tissue sarcomas, and served as the Global Clinical Leader for the breakthrough therapy daratumumab (DARZALEX®) for hematologic cancers.
“I look forward to working with the outstanding team at Pyramid Biosciences, progressing the Company’s promising therapies through clinical development and building a robust pipeline,” said Dr. Khokhar.
“We are extremely pleased to have Nushmia join our senior leadership team as we continue to grow our clinical programs and develop new medicines for underserved patients,” said Jordan Leef, Pyramid Biosciences’ Co-Founder & COO.
Dr. Khokhar is a graduate of Aga Khan University and completed her post-doctoral fellowship at Memorial Sloan-Kettering Cancer Center, where she focused on pharmacology and molecular therapeutics. Following her post-doctoral fellowship, Dr. Khokhar completed a residency in internal medicine at Washington Hospital Center and a fellowship in Hematology/Oncology at the Northwestern University Hospital. Dr. Khokhar is board certified in medical oncology.
About Pyramid Biosciences:
Founded in 2015, Pyramid Biosciences is a clinical-stage biotechnology company dedicated to developing a portfolio of precision therapies targeting a targeting a range of serious diseases. Pyramid is currently in clinical development of two highly selective tropomyosin receptor kinase (TRK) inhibitors. For more information, please visit: www.pyramidbio.com
Contacts
Pyramid Biosciences Media Inquiries:
McDougall Communications on behalf of Pyramid Biosciences
Elizabeth Harness, +1-585-435-7379
[email protected]
Pyramid Biosciences Investor Inquiries:
Jordan Leef, Pyramid Biosciences, COO, CBO, and Co-Founder
+1-781-530-4461, [email protected]